The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Clinical & Research NewsFull Access

Comparing PANSS, BPRS Results

Published Online:https://doi.org/10.1176/pn.38.13.0019

Two scales for measuring symptom reduction of schizophrenia patients are commonly used in clinical trials, making comparisons of data across studies a challenge at best.

The Brief Psychiatric Rating Scale (BPRS) is a 16-item scale with nine general symptom items, five positive-symptom items, and two negative-symptom items. Completed by the physician, each item is scored on a seven-point severity scale (the higher the number, the more severe the symptom), resulting in a range of possible scores from 16 to 112. The average patient with schizophrenia entering a clinical trial typically scores 33.

The Positive and Negative Syndrome Scale (PANSS) is a 30-item scale with 16 general psychopathology symptom items, seven positive-symptom items, and seven negativesymptom items. Also completed by the physician, each item is scored on the same sevenpoint severity scale as the PANSS, resulting in a range of possible scores from 30 to 210. The positive- and negative-symptom item groups are often reported separately, with a possible range of 7 to 49. A patient with schizophrenia entering a clinical trial typically scores 91.

Source:Geddes J et al; BMJ 2000; 321:1371-76.